Study on Gocatamig and Infinatamab Deruxtecan for Treating Small Cell Lung Cancer

Inclusion Criteria

• Have a confirmed diagnosis of extensive-stage small cell lung cancer (ES-SCLC).
• For those receiving Gocatamig and I-DXd as maintenance treatment:
  • Completed 3 to 4 cycles of chemotherapy with platinum and etoposide, along with an approved immunotherapy, as the first treatment for ES-SCLC within 6 weeks before joining the study.
  • No signs of cancer progression on scans.
  • No other previous treatments for ES-SCLC.
  • Repeated treatment counts as a new line of therapy and leads to exclusion.
• For those receiving Gocatamig and I-DXd in different treatment phases, no prior treatment for ES-SCLC is allowed.
• Previous limited-stage small cell lung cancer is allowed if more than 6 months have passed since the last treatment and the cancer has progressed.
• Must provide a tumor sample from before treatment or a new biopsy from a tumor that hasn't been treated with radiation.
• Must have measurable disease as determined by scans, even if the tumor was previously treated with radiation, as long as it has grown since then.

Exclusion Criteria

• Have fluid buildup around the lungs, heart, or abdomen that needs frequent drainage.
• Have a history of lung diseases like interstitial lung disease or pneumonitis, or current lung issues that can't be ruled out by scans.
• Have severe lung problems due to other illnesses.
• Have a history of serious bleeding in the brain or spinal cord.
• Have active neurological conditions related to cancer.
• Have had recent heart surgeries or serious heart conditions like heart attacks or heart failure within 6 months before starting the study.
• Have other serious heart diseases as specified in the study.
• Have had a blood clot in an artery within 6 months before starting the study.
• Have chronic liver disease.
• Have had a tissue or organ transplant.
• Have a history of cancer spreading to the brain or spinal cord lining.
• Have HIV with a history of certain related diseases.
• Have received certain immunotherapy treatments before.
• Have had radiation therapy within 2 weeks before starting the study or have side effects from radiation that need steroids.
• Have another active cancer that has needed treatment in the past 3 years.
• Have an active autoimmune disease needing treatment in the past 2 years, except for replacement therapy.
• Have active cancer spread to the brain or spinal cord lining.
• Have had major surgery within 4 weeks or minor surgery within 2 weeks before starting the study, or need major surgery during the study.